INCY
USDIncyte Corp. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$101.360
Máximo
$103.860
Mínimo
$100.020
Volumen
2.74M
Fundamentos de la Empresa
Capitalización de Mercado
20.2B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
2.00M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Piper Sandler Maintains Overweight on Incyte, Raises Price Target to $102
Piper Sandler analyst Allison Bratzel maintains Incyte with a Overweight and raises the price target from $82 to $102.
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Guggenheim Upgrades Incyte to Buy, Announces $125 Price Target
Guggenheim analyst Michael Schmidt upgrades Incyte from Neutral to Buy and announces $125 price target.
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated
Incyte to Present at Upcoming Investor Conferences
Incyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of November: Guggenheim Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 10:00
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
MONTREAL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX:GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM
RBC Capital Maintains Sector Perform on Incyte, Raises Price Target to $84
RBC Capital analyst Brian Abrahams maintains Incyte with a Sector Perform and raises the price target from $81 to $84.
Acciones Relacionadas
IINN
Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares
ALL
Allstate
ZVSA
ZyVersa Therapeutics Inc.
EXTO
Almacenes Exito S.A. American Depositary Share each representing eight (8) Common Shares
BDTX
Black Diamond Therapeutics Inc.
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.